Genelux Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
26
- Stock Symbol
-
GNLX
- Investments
-
1
- Share Price
-
$2.16
- (As of Friday Closing)
Genelux General Information
Description
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
Contact Information
Website
www.genelux.comCorporate Office
- 2625 Townsgate Road
- Suite 230
- Westlake Village, CA 91361
- United States
Corporate Office
- 2625 Townsgate Road
- Suite 230
- Westlake Village, CA 91361
- United States
Genelux Timeline
Genelux Stock Performance
As of 20-Nov-2026, Genelux’s stock price is $2.16. Its current market cap is $103M with 47.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.16 | $2.28 | $1.77 - $5.89 | $103M | 47.6M | 332K | -$0.88 |
Genelux Financials Summary
As of 30-Sep-2026, Genelux has a trailing 12-month revenue of $8K.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 98,221 | 147,615 | 49,492 | 346,342 |
| Revenue | 8 | 8 | 8 | 170 |
| EBITDA | (38,191) | (32,640) | (30,423) | (26,701) |
| Net Income | (37,932) | (32,145) | (29,869) | (28,297) |
| Total Assets | 20,612 | 19,027 | 34,716 | 27,893 |
| Total Debt | 2,344 | 1,685 | 1,868 | 2,519 |
Genelux Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Genelux Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Genelux Comparisons
Industry
Financing
Details
Genelux Competitors (72)
One of Genelux’s 72 competitors is Aura Biosciences, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aura Biosciences | Formerly VC-backed | Boston, MA | ||||
| Sutro Biopharma | Formerly VC-backed | South San Francisco, CA | ||||
| ORIC Pharmaceuticals | Formerly VC-backed | South San Francisco, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Oncorus | Formerly VC-backed | Andover, MA |
Genelux Patents
Genelux Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-2023544184-A | Bioreactor generation of viruses from adherent cells | Inactive | 02-Oct-2020 | ||
| EP-4222250-A1 | Bioreactor production of virus from adherent cells | Pending | 02-Oct-2020 | ||
| JP-2025118611-A | Bioreactor production of virus from adherent cells | Pending | 02-Oct-2020 | ||
| WO-2022071966-A1 | Bioreactor production of virus from adherent cells | Inactive | 02-Oct-2020 | ||
| US-10851350-B1 | Bioreactor production of virus from adherent cells | Active | 27-Jun-2017 | C12N7/02 |
Genelux Signals
Genelux Investments (1)
Genelux’s most recent deal was a Joint Venture with V2ACT Therapeutics. The deal was made on 01-Jan-2019.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| V2ACT Therapeutics | 01-Jan-2019 | Joint Venture | Drug Discovery |
Genelux ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
40.3 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Genelux FAQs
-
When was Genelux founded?
Genelux was founded in 2001.
-
Where is Genelux headquartered?
Genelux is headquartered in Westlake Village, CA.
-
What is the size of Genelux?
Genelux has 26 total employees.
-
What industry is Genelux in?
Genelux’s primary industry is Drug Discovery.
-
Is Genelux a private or public company?
Genelux is a Public company.
-
What is Genelux’s stock symbol?
The ticker symbol for Genelux is GNLX.
-
What is the current stock price of Genelux?
As of 20-Nov-2026 the stock price of Genelux is $2.16.
-
What is the current market cap of Genelux?
The current market capitalization of Genelux is $103M.
-
What is Genelux’s current revenue?
The trailing twelve month revenue for Genelux is $8K.
-
Who are Genelux’s competitors?
Aura Biosciences, Sutro Biopharma, ORIC Pharmaceuticals, Adaptimmune Therapeutics, and Oncorus are some of the 72 competitors of Genelux.
-
What is Genelux’s annual earnings per share (EPS)?
Genelux’s EPS for 12 months was -$0.88.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process